Calidi Biotherapeutics, Inc.
CLDI
$0.19
$0.015.24%
AMEX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 10.10% | 24.08% | 14.60% | 33.61% | 24.21% |
| Total Depreciation and Amortization | 7.56% | 7.64% | 8.42% | 7.46% | 22.21% |
| Total Amortization of Deferred Charges | -- | 101.68% | 128.26% | -88.26% | -89.58% |
| Total Other Non-Cash Items | -33.58% | 5.22% | 189.67% | -59.78% | -62.18% |
| Change in Net Operating Assets | -179.33% | -254.38% | -42.31% | -53.40% | 72.80% |
| Cash from Operations | -8.12% | -11.38% | 20.15% | 17.01% | 27.01% |
| Capital Expenditure | -650.00% | -18.52% | 48.98% | 96.03% | 97.26% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -962.50% | -108.70% | 27.18% | 94.80% | 96.65% |
| Total Debt Issued | -- | -100.00% | -81.25% | -85.37% | 16.92% |
| Total Debt Repaid | -32.31% | 40.35% | 49.62% | -49.72% | 19.95% |
| Issuance of Common Stock | -27.16% | 222.38% | 393.72% | 32,846.00% | 8,038.79% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 27.67% | 20.26% | -71.28% | 26.82% | -23.46% |
| Cash from Financing | -36.20% | 167.45% | -0.37% | 14.84% | -5.78% |
| Foreign Exchange rate Adjustments | 207.69% | 145.83% | -237.50% | -372.73% | -116.67% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -152.21% | 202.78% | 451.06% | 4,104.46% | 384.59% |